Cancer Vaccines: European Immunotherapy Strategies

European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.

The concept of vaccination is well-validated in infectious diseases but the recent flurry of attempts to enlist the body's T-cells and antibodies to recognize and destroy cancer have not yet borne fruit. These cancer vaccines however have shown clinical promise against various guises of the terminal illness and importantly, do so without the debilitating side effects associated with many existing radio- and chemotherapies. The unmet medical need has created a highly competitive subgroup of oncology firms jockeying with each other and with regulatory authorities to bring these immunotherapies to market.

However worthwhile the cause, the road to approval of a cancer vaccine has proven to be an uphill one. Positive...

More from Global Vision

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.